Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2018 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018

WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
May 17, 2018 08:00 ET | Source: Minerva Neurosciences, Inc

Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
May 03, 2018 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates

WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
April 26, 2018 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018

WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
April 09, 2018 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder

WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
March 15, 2018 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22

WALTHAM, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system...
March 12, 2018 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates

Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at...
March 05, 2018 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
February 05, 2018 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director

WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)...
December 21, 2017 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder

WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...